KR

Karl Rothweiler

Aglaia is an early-stage venture capital firm focused on building next-generation life science companies. Aglaia takes an active role in building companies from scratch.

De Bilt, Utrecht

Investor
VC

Invests in

Stages:

Series A
Seed

Locations:

Netherlands

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Corporate Law
Corporate Finance
Startups
Mergers & Acquisitions (M&A)
Business Development
Business Strategy

Education

Lists including Karl

AM
Al
AF
AV

Based in Amsterdam

273 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Work Experience

AO
Aglaia Oncology Funds

2004

  • Managing Partner

    2004

IB
Inthera Bioscience AG

2022

  • Founding Investor, Member of the Supervisory Board

    2022

ST
Sapreme Technologies BV

2016

  • Founder, Founding Investor, Member of the Supervisory Board

    2016

    Member of the Remuneration Committee (Board)

MP
Modra Pharmaceuticals

2015

  • Founding Investor, Member of the Supervisory Board

    2015

    Member of the Audit Committee (Board)

MN
Merus N.V.

2005

  • Founding Investor

    2005

    Sole investor during the 4-year start-up phase of this great Unicorn.

InteRNA Technologies BV

2006 - 2023

  • Founder, Founding Investor, Member of the Supervisory Board

    2006 - 2023

    Member of the Audit Committee (Board)

IP
ISA Pharmaceuticals

2004 - 2017

  • Founder, Founding Investor, Member of the Supervisory Board

    2004 - 2017

    Member of the Board following the incubation of and founding investments in the company.

OT
ORCA Therapeutics

2005 - 2013

  • Founder, Founding Investor

    2005 - 2013

Syntarga

2005 - 2011

  • Founding Investor, Member of the Supervisory Board

    2005 - 2011

    Pivital role in the sale of the company to Byondis.

Entity Holding

1995 - 2004

  • Founder

    1995 - 2004

    Early stage venturing in the internet space